Quest Diagnostics Posts Double-Digit Revenue Growth, Raises 2026 Guidance
Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth in the second quarter of 2026 and raised its full-year guidance. The growth was fueled by strong demand across physician, hospital, and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medical Care.
Key Numbers
Quest Diagnostics (NYSE:DGX) announced double-digit revenue growth for the second quarter of 2026, driven by robust demand across its physician, hospital, and consumer channels, along with increased testing volume from its partnerships with Corewell Health and Fresenius Medical Care. Based on these results, the company raised its full-year 2026 guidance.
Key Financial Results
| Metric | Value |
|---|---|
| Revenue Growth | Double-digit |
| Net Income | Not disclosed |
| EPS | Not disclosed |
| YoY Comparison | Not provided |
Highlights from the Call
Management attributed the strong performance to the company's strategy of expanding services across multiple channels and strengthening strategic partnerships. The collaborations with Corewell Health and Fresenius Medical Care were highlighted as significant contributors to volume growth.
Future Guidance
Quest Diagnostics raised its full-year 2026 guidance. Specific figures for the updated guidance have not yet been released.
Stock Impact
The announcement is expected to positively impact DGX shares, particularly with the guidance raise. However, immediate stock reaction was not reported.
What This Means for Investors
The strong performance demonstrates resilient demand for diagnostic laboratory services and the company's ability to diversify revenue streams through partnerships. The guidance raise boosts confidence in management's ability to deliver sustainable growth, though investors await precise figures for further assessment.
Frequently Asked Questions
Found this useful? Share it